# A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

> **NCT00002362** · PHASE3 · SUSPENDED · sponsor: **Triangle Pharmaceuticals**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Abacavir sulfate
- **DRUG:** Efavirenz
- **DRUG:** Emtricitabine
- **DRUG:** Stavudine

## Key facts

- **NCT ID:** NCT00002362
- **Lead sponsor:** Triangle Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 1999-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002362, "A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00002362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*